Changes of serum anti survivin antibody in patients with advanced primary liver cancer before and after TACE and its relationship with prognosis
10.3760/cma.j.cn113855-20230302-00103
- VernacularTitle:中晚期原发性肝癌患者经导管肝动脉化疗栓塞术前后血清抗Survivin抗体变化及其与患者预后的关系
- Author:
Guanqun LI
1
;
Chaojie LIANG
;
Jixiang WU
Author Information
1. 首都医科大学附属北京同仁医院普外科，北京 100730
- Keywords:
Liver neoplasms;
Chemoembolization,therapeutic;
Anti apoptosis inhibitor antibody;
Prognosis
- From:
Chinese Journal of General Surgery
2023;38(9):669-673
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of anti apoptosis inhibitor antibody in serum of patients with advanced primary liver cancer and its relationship with the prognosis after transcatheter hepatic arterial chemoembolization (TACE).Methods:One hundred and three patients with advanced primary liver cancer were selected from our hospital and treated with TACE. Serum anti-survivin antibody expression levels were detected 1 day before surgery and 1 month after surgery. To analyze the relationship between serum anti-survivin antibody level and short-term therapeutic effect, clinicopathological features and prognosis were analyzed.Results:the level of anti-survivin antibody in patients with disease remission was significantly lower than that in patients without disease remission (81.84±9.30 vs. 90.84±10.21, P<0.05), and the change of anti-survivin antibody in patients with disease remission was significantly higher than that in patients without disease remission (30.93±5.63 vs. 22.75±4.52, P<0.05). The changes of anti-survivin antibody before and after TACE were correlated with TNM stage, maximum tumor diameter and degree of differentiation ( P<0.05). The results of survival analysis showed that the postoperative survival of patients with △ reduced anti-survivin antibody was significantly better than that of patients without △ reduced anti-survivin antibody ( P<0.05). The area under the ROC curve was 0.850 in the prediction of one-year death value of patients with primary liver cancer by △ anti-survivin antibody. Conclusion:the difference of anti survivin antibody before and after TACE in patients with advanced liver cancer is closely related to the short-term and long-term prognosis.
